The U.S. Food and Drug Administration (FDA) approved Yupelri (revefenacin) for the maintenance treatment of patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [1]. It is administered as a once-daily inhalation [1].
What is Yupelri used for?
Yupelri is indicated for the long-term maintenance treatment of airflow obstruction in patients with moderate to very severe COPD [1]. It is not intended for the relief of acute bronchospasm [1].
How does Yupelri work?
Yupelri is a long-acting muscarinic antagonist (LAMA) [1]. It works by blocking the action of acetylcholine on muscarinic receptors in the airway smooth muscle, leading to bronchodilation [1]. This helps to relax and widen the airways, making it easier to breathe [1].
What are the potential side effects of Yupelri?
The most common side effects reported in clinical trials include [1]:
* Nasopharyngitis (common cold symptoms)
* Upper respiratory tract infection
* Bronchitis
* Headache
* Diarrhea
* Nausea
* Back pain
* Sinusitis
* Influenza
* Toothache
* Urinary tract infection
* Cough
* Dizziness
* Rash
Serious side effects can include paradoxical bronchospasm, cardiovascular effects, glaucoma, urinary retention, and hypersensitivity reactions [1].
When did Yupelri receive FDA approval?
Yupelri was approved by the FDA on October 25, 2018 [1].
What is the recommended dosage for Yupelri?
The recommended dosage of Yupelri is 175 mcg inhaled once daily [1]. It is supplied as a solution for nebulization [1].
Are there any contraindications for Yupelri?
Yupelri is contraindicated in patients with a history of hypersensitivity to revefenacin or any of its ingredients [1].
What are the key considerations for prescribing Yupelri?
Prescribers should consider the patient's medical history, including any history of narrow-angle glaucoma, urinary retention, or bladder outlet obstruction, as LAMAs can worsen these conditions [1]. Patients should be advised to use the medication as directed and to seek medical attention if their breathing problems worsen or if they experience any signs of hypersensitivity [1].
What is the patent status of Yupelri?
Information regarding Yupelri's patent status can be found on DrugPatentWatch.com [2]. DrugPatentWatch.com tracks patent and exclusivity information for a wide range of pharmaceuticals, which can be crucial for understanding market entry timelines for generic or biosimilar versions [2].
How does Yupelri compare to other COPD treatments?
Yupelri is a LAMA, and other LAMAs used for COPD include tiotropium, aclidinium, and umeclidinium [3]. It is also part of a class of medications that includes long-acting beta-agonists (LABAs) and inhaled corticosteroids (ICS), which are often used in combination therapies for COPD management [3]. The choice of treatment depends on the severity of the COPD, the patient's response to therapy, and individual risk factors [3].
Where can I find more information on COPD treatment guidelines?
For comprehensive guidelines on COPD management, consult resources from organizations such as the Global Initiative for Chronic Obstructive Lung Disease (GOLD) [4] or the American Thoracic Society (ATS) [5].
*
**Sources:
1. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-certifications
2. https://drugpatentwatch.com/
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6565186/
4. https://goldcopd.org/
5. https://www.thoracic.org/